Register by December 4th
and Save up to $698
Hear from Leading
Experts Including:
David J. Payne, PhD
Vice President, Antibacterial DPU,
Infectious Diseases Center of Excellence
Anti-Infectives
in Drug Discovery
TM GlaxoSmithKline
John Finn, PhD
Chief Scientific Officer
Trius Therapeutics
Jeffrey M. Besterman, PhD
Executive Vice President,
R & D and CSO
Summit
MethylGene Inc.
Malcolm Page, PhD
January 25-27, 2010 • Philadelphia, PA Head, Biology
Basilea Pharmaceutical
International Ltd
Adam Friedman, MD
Groundbreaking Advances and Key Chief Resident, Department of Medicine,
Division of Dermatology
Opinions within Anti-Infective Drug Albert Einstein College of Medicine
Nkechi Azie, PhD
Discovery and Development Senior Medical Director
Astellas Pharma US
Baoming Jiang, DVM, PhD
Gastroenteritis & Respiratory
Viruses Lab Branch
Centers for Disease Control and
Prevention
Ly Tam Phan, PhD
Senior Director, Medicinal Chemistry
Enanta Pharmaceuticals
Nachum Kaplan, PhD
Vice President, Microbiology
Affinium Pharmaceuticals
Neil Ryder, PhD
Executive Director, Infectious Diseases
Novartis Institutes for Biomedical
Research
Paul Miller, PhD
Executive Director, Anti-Bacterials
Highlights of this program include: Pfizer
Vincent Hernandez
• Formulating an appropriate novel anti-infective drug development Senior Scientist
pipeline Medicinal Chemistry
Anacor Pharmaceuticals
• Examining the changing fortunes of antibacterial drug development William Weiss, PhD
and commercialization Director of Pre-Clinical Services
University Of North Texas Health
• Discovering where the next novel antibacterial leads will come from Science Center
Scott Mills, PhD
• Ascertaining which biologics may play a role in anti-infective therapy Principal Scientist
AstraZeneca
• Uncovering real challenges and potential solutions for multi-drug
resistant gram-negative bacteria Chris Thomson, PhD
Director, Licensing & Business
Development
Astellas Pharma Europe Ltd
Neil D. Pearson, PhD
Media Director, Medicinal Chemistry,
Partners: Antibacterial DPU, Infectious Diseases
Center of Excellence in Drug Discovery
GlaxoSmithKline
John Powers, MD
Assistant Professor of Medicine
George Washington University
School of Medicine and former Lead
Medical Officer, Antimicrobial
www.anti-infectivesummit.com Development, US FDA

Who will you meet at
the Summit:
Anti-Infectives
TM
Chief Scientific Officers, Vice Presidents,
Directors, Heads, Scientists, Chemists,
Research Leaders/Fellows/Advisors and
Academics specializing in:
• Microbiology
• Immunology
Infectious Diseases
Summit
•
• Medicinal Chemistry
• Clinical Pharmacology
January 25-27, 2010 • Philadelphia, PA • Drug Discovery
• New Product Development
• Scientific Affairs
• Licensing
• Antibiotics
• Infection Discovery
• Drug evaluation
• Molecular Biotechnology
Dear Colleague, • Drug Development
• Project Management
• Preclinical Development
IQPC’s Anti-Infectives Summit aim • Portfolio Management
s to provide an opportunity for R&D
from pharmaceutical, biotech and leaders • Anti-bacterial/viral/fungal and
academia to expand their knowle Microbiological Infections
anti-infectives industry as well as dge in the
ascertain new opportunities for drug
discovery.
The need for new agents to com
challenges and significant market
bat increasing drug-resistance has
created both A Special Thanks to our
opportunities for pharmaceutical Advisory Board:
manufacturers and biotechnology
companies. A more integrated app
needed from industry, academia roach is • Malcolm Page, PhD, Head, Biology,
and government to improve the
pipeline as the demand for new anti-infectives Basilea Pharmaceutical International Ltd
therapies increases. • Neil Ryder, PhD, Executive Director,
You will hear over 16 in-depth sess Infectious Diseases, Novartis Institutes for
ions and case study examples inclu Biomedical Research
•
Targeting superbugs: New Bicycloli ding:
des effective against MRSA and VRE • David J. Payne, PhD, Vice President,
•
A novel regimen for the treatment Antibacterial DPU, Infectious Diseases
of TB Center of Excellence in Drug Discovery,
•
Sustained release of nitric oxide from
hybrid nanoparticle platforms GlaxoSmithKline
•
Emerging market countries and infe Paul Miller, PhD, Executive Director,
ctious disease needs •
•
Multi-Drug Resistant Gram-Nega Anti-Bacterials, Pfizer
tive Bacteria - Real challenges and
potential solutions • Frederick P. Duncanson, MD, Senior
Director, Section Head Infectious Diseases,
•
Bacterial Fatty Acid Synthesis as targ Neurosciences Product, Creation Unit, Eisai
et for AFN-1252, a novel and
selective-spectrum Global Clinical Development
•
ntibiotics for the treatment of stap • Anne Gershon, M.D, Vice President and
hylococcal Infection President-Elect, Infectious Diseases
•
Anti-Infective drug discovery thro Society of America (IDSA)
ugh outsourcing and collaboration
s • Ronald GM Van Amsterdam, PhD,
Additionally, benefit from industry Principal Medical Scientist, Astellas Europe
presentations by AstraZeneca, Pfiz
GlaxoSmithKline, Trius Therap er, • Arturo Casadevall, MD, PhD, Professor of
eutics, Anacor Pharmaceuticals, Microbiology and Immunology and
Affinium Pharmaceuticals, Me Novartis,
thylGene, Astellas, EnantaPha Medicine, Chair, Department of
and many more pharmaceutical, rmaceuticals,
biotech and academic experts. This Microbiology and Immunology, Albert
promises to be a networking and conference Einstein College of Medicine
discussion-filled event leaving you
ideas and solutions and to help you with new • Hans-Henrik Kristensen,
discover the current novel anti-infe
drug development pipelines. ctive Senior Manager, Novozymes A/S
We look forward to seeing you in
Philadelphia in January!
Sponsorship and
Exhibition Opportunities
ractive
P Highly inte
.S Sponsorships and exhibits are excellent
e pre- opportunities for your company to showcase
and informativ its products and services to high-level, targeted
rkshops! decision-makers attending Anti-Infectives
Simon Curtis conference wo Summit. IQPC and Pharma IQ help companies
or details
Se e page 5 f
Conference Director, Pharma IQ like yours achieve important sales, marketing
and branding objectives by setting aside a
Simon.curtis@iqpc.com limited number of event sponsorships and
exhibit spaces – all of which are tailored to
assist your organization in creating a platform
to maximize its exposure at the event.
For more information on sponsoring or
exhibiting at Anti-Infectives Summit, please
contact Mario Matulich at 212-885-2719 or
2 Register online at www.anti-infectivesummit.com or call 1-800-882-8684 sponsorship@iqpc.com.

Main Conference Day 1 Tuesday, January 26, 2010
7:45 Registration and Coffee Novel Therapeutic Approaches and Areas
8:35 Welcome Address and 1:30 Discovering Novel Candidates Affective Against
Chairperson’s Opening Remarks Superbugs (Torezolid [TR-701] Case Study)
• Discussing effective results for the treatment of severe complicated
The Current Anti-Infective Drug Discovery & skin and skin structure infections caused by gram-positive bacteria
Development Market Landscape • Displaying positive results especially against drug-resistant strains
such as methicillin-resistant Staphylococcus aureus (MRSA)
8:45 Opening Keynote: Industry Overview - The • Describing a randomized Phase 2, double-blind, dose-ranging study
Current Shape of Anti-Bacterial R&D conducted at eight centers in the United States
• Knowing which direction the anti-bacterials market is heading • Examining overall cure rates for severe abscesses, cellulitis, and
• Examining the emergence & challenges of novel drug classes wound infections which were 96%, 97%, and 90%, respectively
• Evaluating narrow vs broad spectrum • Evaluating a second-generation oral and IV antibacterial drug in the
• Bridging the funding gap
oxazolidinone class with activity against drug-resistant, gram-
• Discussing new strategies and creative partnerships for improving
positive bacterial pathogens, including those resistant to linezolid
success John Finn, PhD, Chief Scientific Officer, Trius Therapeutics
David J. Payne, PhD, Vice President Antibacterial DPU,
Infectious Diseases Center of Excellence in Drug Discovery, 2:15 Targeting Superbugs: New Bicyclolides Effective
GlaxoSmithKline against MRSA and VRE
• Discussing recent advances in macrolide research against MRSA and
9:30 Paradise Lost, Paradise Found? - The Changing VRE
• Identifying targeted product profiles
Fortunes of Antibacterial Drug Development and • Uncovering the history and discovery of new anti-MRSA macrolides
Commercialization • Overcoming bacterial resistance
• Changing Environment & Dynamics of Antibacterial Development • In vitro and In vivo activities
and Commercialization Ly Tam Phan, PhD, Senior Director Medicinal Chemistry, Enanta
• Displaying the steps to become sustainable reinforcement as a Global
Pharmaceuticals, Inc.
Category Leader (GCL) within the infectious diseases drug discovery
arena 3:00 Towards a Novel Regimen for the Treatment of TB:
• Current trends – evolving resistance and decreasing investment levels
• Understanding current antibacterial market dynamics
An Update on PNU-100480
• Examining future pipelines and their implications
• Examining the current state of TB therapy and the challenge of
increasing medical need
Chris Thomson, PhD, Director, Licensing & Business • Displaying updates on ongoing clinical studies with PNU-100480
Development, Astellas Pharma Europe Ltd • Discussing the current status of the global TB drug candidate
portfolio
10:15 Networking Break • Evaluating novel strategies for identifying promising new TB
regimens
Novel Anti-Infective Drug Development Paul Miller, PhD, Executive Director, Anti-Bacterials, Pfizer
Approaches
3:45 Networking Break
11:00 Formulating an Appropriate Novel Anti-Infective
Drug Development Pipeline 4:30 Sustained Release of Nitric Oxide from Hybrid
• Formulating a senior management buy-in for your organization to Nanoparticle Platform: A Novel Therapeutic
fight against withdrawing from multidrug-resistant bacteria Strategy for Cutaneous Infections
development pipelines • The role of nitric oxide in host immunity/defense
• Strategically working with a partnering organization or spin-off who • Nanotechnology as a delivery system for topical therapeutics
focus specifically within certain anti-infective areas • Novel hybrid nitric oxide releasing nanoparticles
• Effectively forging a strategic biotech alliance, for optimizing the • Efficacy of nitric oxide releasing nanoparticles against Methicillin
development pipeline Resistant Staphylococcus aureus wound and soft tissue infections
• Future directions and organisms to be targeted
• Successful drug development can shoulder most of the responsibility
for developing the next generation of anti-infectives Adam Friedman, MD, Chief Resident, Department of Medicine,
• Seeking to build product portfolios within specific anti-infective Division of Dermatology, Albert Einstein College of Medicine
therapeutic areas (case study)
Nkechi Azie, MD, Senior Medical Director, Astellas Pharma US The Global Growth of Infectious Diseases
11:45 Improving Antibacterial Discovery: A Critical Path 5:15 Emerging Market Countries and Infectious Disease
for Minimizing Attrition Due to CV Liabilities Needs
• Acute functional cardiovascular toxicity: a special consideration for
• Effectively addressing the global threat of new and reemerging
infectious diseases
antibiotic drug discovery • Inducing international cooperation in identifying, controlling, and
• Understanding QT liability and Torsade de Pointes (TdP) during lead
preventing these diseases
optimization • Examining some basic problems that global campaigns against
• Role of hERG inhibition in QT prolongation and Torsade de Points
• Beyong hERG assays for predicting TdP risk: Rabbit Ventricular
emerging infectious diseases face in applying international law to
facilitate international cooperation
Wedge assay • Discussing international solutions to emerging infections
• Lead optimization for antibacterial programs with respect to acute
• Identifying common elements of global emerging-disease control
functional cardiovascular toxicity plans
Neil D. Pearson, PhD, Director Medicinal Chemistry, • Evaluating alternative international legal strategies to revising the
Antibacterial DPU, Infectious Diseases Center of Excellence in International Health Regulations
Drug Discovery, GlaxoSmithKline Baoming Jiang, DVM, PhD, Gastroenteritis & Respiratory Viruses
Lab Branch, Centers for Disease Control and Prevention
12:30 Networking Lunch
6:00 Chairperson’s Remarks and End of Day 1
3 Register online at www.anti-infectivesummit.com or call 1-800-882-8684

Main Conference Day 2 Wednesday, January 27, 2010
7:45 Registration and Coffee Novel Therapeutic Approaches
8:35 Welcome Address and Chairperson’s Opening 1:30 Bacterial Fatty Acid Synthesis as Target for AFN-
Remarks 1252, a Novel and Selective-Spectrum Antibiotic
for the Treatment of Staphylococcal Infection
Update on Antifungals • Unique mechanism of action, selective inhibitor of staphylococcal
fatty acid biosynthesis
8:45 Approaches to Novel Antifungal Therapies • Highly potent, optimized to inhibit the staphylococcal FabI enzyme
• Finding antifungal targets • Preclinical safety and a selective-spectrum of activity predict minimal
• Understanding the role of resistance mechanisms antibiotic treatment related adverse effects
• Biologics and other novel approaches • Orally effective in multiple mouse infection models (pneumonia,
• Evaluating approaches to modify existing antifungals (polyenes sepsis, thigh and skin abscesses)
• Well tolerated in phase 1 clinical studies
and azoles)
• Introducing novel therapies (peptides, oligonucleotides, and Nachum Kaplan, PhD, Vice President, Microbiology, Affinium
monoclonal antibodies (MAbs)) Pharmaceuticals
Neil Ryder, PhD, Executive Director, Infectious Diseases,
Novartis Institutes for Biomedical Research 2:15 Target-Based Screening: Discovery of Novel
Inhibitors of Bacterial NAD+-Dependent DNA Ligase
9:30 Addressing Serious Fungal Infections & Broad •
Discussing in vitro validation of DNA ligase as a target for high
Spectrum Clinical Candidates throughput screening
• Optimizing potency of enzyme inhibition to achieve antibacterial
• Discussing fungi present in the gastrointestinal tract (Candida) or
activity
in the environment (Aspergillus) • Linking antibacterial activity to inhibition of DNA ligase
• Displaying a novel small molecule fungal Hos2 inhibitor that
• Achieving in vivo validation of DNA ligase via efficacy in infection
enhances the activity and spectrum of current azole treatments model
against fungal pathogens when co-administered with azoles Scott Mills, PhD, Principal Scientist, AstraZeneca
• Demonstrating how MGCD290 enhances the azole susceptibility
of common fungal pathogens such as Candida and Aspergillus 3:00 Networking Break
species
• Possessing a broad-spectrum inhibitory profile for both class A and
Future Anti-Infective Drug Discovery Techniques
class C beta-lactamase enzymes, including extended spectrum & Strategies
betalactamases (ESBLs)
• Overcoming resistance in beta-lactam-resistant organisms such as
3:30 Anti-Infective Drug Discovery through
Pseudomonas aeruginosa
Jeffrey M. Besterman, PhD, Executive Vice President, R & D
Outsourcing and Collaborations
• Examining the current paradigm of anti-infective drug discovery
and CSO, MethylGene Inc. • Discussing how and why companies are moving compounds ahead
when many larger groups have downsized their infectious disease
10:15 Networking Break efforts
• Utilizing partners to help overcome significant challenges to public
Gram-Positive & Gram-Negative Bacteria healthcare arising from drug resistant bacteria
• Progression of anti-infective drug discovery and development
11:00 Multi-Drug Resistant Gram-Negative Bacteria - through the provision of a comprehensive range of highly
Real challenges and potential solutions specialized services to the pharmaceutical, biotechnology and
• Problem pathogens (drug-resistance in E. coli, K. pneumoniae, P. consumer healthcare sectors
• The use and role of the academic collaborator, scientific incubator,
aeruginosa and A. baumannii)
• Resistance mechanisms in E. coli and K. pneumoniae CRO and CMO – what they need to know to accelerate drug
• Resistance mechanisms in P. aeruginosa and A. baumannii development
• Current research collaborations for new drug discovery: Big Pharma
•
Activity of new agents, and compounds in late-stage clincal
development, against MDR and Biotech
• Activity of experimental compounds in early stage clinical
William Weiss, PhD, Director of Pre-Clinical Services, University
of North Texas Health Science Center
development
Malcolm Page, PhD, Head, Biology, Basilea Pharmaceutical
International Ltd
4:15 Addressing the Challenge of Fungal Infections:
What are our Options?
• Discussing fungi such as Aspergillus fumigatus cause a variety of
11:45 Structure-Guided Discovery of serious nosocomial infections in immunocompromised patients
(S)-3-(aminomethyl)benzo[c][1,2]oxaborol-1(3H)- •
Resulting with their resistance to antibiotics has profound clinical
ol hydrochloride (ABX): A First in Class Gram- implications
negative Antibacterial • Displaying the three antibiotic classes which are currently in clinical
• Examining structure-based design of boron-containing use for fungal infections: amphotericin, echinocandins and azoles
antibacterial agents • Examining why all of these classes have efficacy and toxicity
• Editing active site of Leucyl tRNA synthetase as a novel drug target
drawbacks
• In vitro activity of ABX against multi-drug resistant Gram negative • Identifying and discussing approaches towards achieving this include:
– Derivatization of echinocandins and azoles
bacteria
• Discussing oral efficacy of ABX in mouse thigh infection models – Potentiation by modulating resistance mechanisms targeting
Vincent Hernandez, Senior Scientist, Medicinal Chemistry, other fungal functions
– Importing insights from antiprotozoal and anticancer agents.
Anacor Pharmaceuticals
Nafsika Georgopapadakou, PhD, Vice President, Research,
NovaBay Pharmaceuticals
12:30 Networking Lunch
5:00 End of Summit & Chairperson’s Closing Remarks
4 Register online at www.anti-infectivesummit.com or call 1-800-882-8684

Pre-Conference Workshops Monday, January 25, 2010
9:00 am – 12:00 pm (Registration 8:30 am)
A Bridging the Scientific and Regulatory Interface For Anti-Infective Drug Development
Planning to address both regulatory and scientific issues can speed a
company’s time to market on a particular anti-infective drug development How you will benefit:
pipeline. Failure to appropriately plan and design studies can delay the •
Discover how to avoid failure within phase 3 clinical trials and overall
clinical phases of development which can cost millions of dollars and drug development plans
potentially end a drug development company’s pipeline prior to product •
Keep up to date on the changing regulatory landscape within the anti-
launch. Knowing effective regulatory guidelines and a scientific framework infectives arena
within which to work is a key goal for companies to speed up their clinical •
Benchmark your development pipeline with a number of successful
development processes for Anti-Infective drug products. leading clinical drug development organizations
•
Keep up to speed with drug development leaders buy hearing effective
What will be covered: implementation strategies
•
Overview of regulatory requirements for drug development within the
anti-infectives market Your workshop Leader:
•
Identifying efficient drug development strategies
John Powers, MD, Assistant Professor of Medicine, George
•
Complying with regulatory requirements quickly and efficiently while
maintaining safety Washington University School of Medicine and former Lead
•
Displaying case study examples of effective and ineffective Medical Officer, Antimicrobial Development, US FDA
implementation
1:00 pm – 4:00 pm (Registration 12:30 pm)
B Phage Therapy within Bacterial Resistance: A Safe and Integrated Approach for the
Management of Superbugs
The workshop will explore a natural and environmentally friendly How you will benefit:
alternative for bacterial resistance: Phage Therapy. Attendees will explore •
Phage product development: Learn how to turn a phage into a
the various potentials of phages in the diagnosis and management of marketable product
bacterial contamination. This session will also focus on how Phage •
Uncover technologies and methodologies, large-scale phage production
treatment and technologies are continuously being used and developed •
Discuss environmental-friendly phage programs to fight bacterial
to combat bacterial infection and help assist drug discovery. contamination
•
Understand when antibiotics are not working anymore and phage
What will be covered:
therapy is an option
•
Phage therapy overview
•
Biosensors
•
Immunology / Immnotoxicology Speaker opportunities available.
•
Early work in Eastern countries and recent advances in phage therapy Please contact Simon.curtis@iqpc.com for more information.
•
Safety issues: groundbreaking announcement from FDA
•
Phage therapy as a personalized medicine combining diagnostic and
phage therapy
Registration Information
Pricing Register by Register by Standard
December 4, 2009 January 8, 2010 Price Venue:
Conference Only (Save $600) (Save $200) Venue is to be announced.
$1,199 $1,599 $1,799 Please check the website at
All Access (Save $698) (Save $298) (Save $98) www.anti-infectivesummit.com
$2,199 $2,599 $2,799
for updates and announcements.
Workshop Only $549 each $549 each $549 each
*All access pass includes conference + all workshops. Details for making payment via EFT or wire transfer:
Please note multiple discounts cannot be combined. JPMorgan Chase - Penton Learning Systems LLC dba IQPC: 957-097239
ABA/Routing #: 021000021
A $99 processing charge will be assessed to all registrations not accompanied by Reference: Please include the name of the attendee(s) and the event number:
credit card payment at the time of registration. 18354.001
MAKE CHECKS PAYABLE IN U.S. DOLLARS TO: IQPC Payment Policy: Payment is due in full at the time of registration and includes
* CT residents or people employed in the state of CT must add 6% sales tax. lunches and refreshment. Your registration will not be confirmed until payment is
Team Discounts: For information on team discounts, please contact IQPC received and may be subject to cancellation.
Customer Service at 1-800-882-8684. Only one discount may be applied per
registrant. For IQPC’s Cancellation, Postponement and Substitution Policy, please visit
www.iqpc.com/cancellation
Special Discounts Available: A limited number of discounts are available for the
Special Dietary Needs: If you have a dietary restriction, please contact Customer
non-profit sector, government organizations and academia. For more information,
Service at 1-800-882-8684 to discuss your specific needs.
please contact customer service at 1-800-882-8684.
©2010 IQPC. All Rights Reserved. The format, design, content and arrangement of this
brochure constitute a trademark of IQPC. Unauthorized reproduction will be actionable under
the Lanham Act and common law principles.
5 Register online at www.anti-infectivesummit.com or call 1-800-882-8684

International Quality & Productivity Center
REGISTRATION CARD 535 5th Avenue, 8th Floor
New York, NY 10017
Anti-Infectives
YES! Please TM
register me for:
❑ Conference Only
Summit
❑ All Access*
❑ Conference + 1 workshop ❑ Workshop(s) Only ❑A ❑B
See Page 5 for pricing details.
Your customer registration code is:
When registering, please provide the code above.
Name__________________________________ Job Title ________________________
Organization____________________________________________________________
Approving Manager______________________________________________________
Address________________________________________________________________
City__________________________________State______________Zip____________
Phone________________________________Fax_______________________________
E-mail__________________________________________________________________ 5 EASY WAYS TO REGISTER:
❑ Please keep me informed via email about this and other related events.
1 Web: www.anti-infectivesummit.com
❑ Check enclosed for $_________ (Payable to IQPC)
2 Call: 1-800-882-8684
❑ Charge my __Amex __Visa __Mastercard __Diners Club
3 Email: info@iqpc.com
Card #__________________________________Exp. Date___/___ CVM code ______
4 Fax: 1-646-378-6025
Details for making payment via EFT or wire transfer can be found on
preceding page. 5 Mail: IQPC
535 5th Avenue, 8th Floor,
❑ I cannot attend, but please keep me informed of all future events. 18354.001/D/AL New York, NY 10017
Register by December 4th
and Save up to $698
Leading Companies
Anti-Infectives
TM to Present:
GlaxoSmithKline
Pfizer, Inc.
AstraZeneca
Summit
January 25-27, 2010 • Philadelphia, PA
Centers for Disease Control
and Prevention
Trius Therapeutics
Groundbreaking Advances and Key Basilea Pharmaceutical
Opinions within Anti-Infective Drug International Ltd
Discovery and Development Affinium Pharmaceutiocals
Anacor Pharmaceuticals
Media Novartis Institute for
Partners: Biomedical research
Astellas Pharma US
Enanta Pharmaceuticals
www.anti-infectivesummit.com MethylGene, Inc.